UK markets closed

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.39-0.50 (-6.34%)
At close: 04:00PM EDT
7.40 +0.01 (+0.14%)
After hours: 06:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.89
Open7.95
Bid7.39 x 600
Ask7.42 x 600
Day's range7.35 - 7.95
52-week range2.09 - 14.84
Volume2,130,240
Avg. volume4,320,033
Market cap523.967M
Beta (5Y monthly)0.20
PE ratio (TTM)N/A
EPS (TTM)-1.60
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date20 Jan 2017
1y target est20.57
  • PR Newswire

    Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

    Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.

  • Simply Wall St.

    Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

    Altimmune ( NASDAQ:ALT ) First Quarter 2024 Results Key Financial Results Net loss: US$24.4m (loss widened by 22% from...

  • GlobeNewswire

    Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

    Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2